1. Home
  2. PAHC vs ANAB Comparison

PAHC vs ANAB Comparison

Compare PAHC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phibro Animal Health Corporation

PAHC

Phibro Animal Health Corporation

HOLD

Current Price

$32.07

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$66.39

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAHC
ANAB
Founded
1946
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
PAHC
ANAB
Price
$32.07
$66.39
Analyst Decision
Hold
Buy
Analyst Count
4
12
Target Price
$41.25
$71.67
AVG Volume (30 Days)
250.7K
634.0K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
0.91%
N/A
EPS Growth
1883.33
91.02
EPS
1.90
N/A
Revenue
$833,350,000.00
$234,603,000.00
Revenue This Year
$17.03
N/A
Revenue Next Year
$3.82
$52.14
P/E Ratio
$17.04
N/A
Revenue Growth
4.12
157.01
52 Week Low
$25.58
$17.11
52 Week High
$60.08
$73.30

Technical Indicators

Market Signals
Indicator
PAHC
ANAB
Relative Strength Index (RSI) 44.94 60.48
Support Level $30.46 $52.32
Resistance Level $34.49 $68.22
Average True Range (ATR) 1.22 3.78
MACD 0.46 0.61
Stochastic Oscillator 40.30 75.87

Price Performance

Historical Comparison
PAHC
ANAB

About PAHC Phibro Animal Health Corporation

Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: